The present disclosure relates to methods and compositions administered to the lymphatic tissue of an animal to prevent or reduce the incidence of disease or disease symptoms caused by one or more disease causing entities. Tonsillar compositions can be administered to the lymphatic tissue in the oral/nasal region of the animal and can include avian antibodies from eggs of hens inoculated with one or more target disease causing entities. Treating the lymphatic tissue in the oral/nasal region with the compositions described herein can reduce or prevent the disease causing entities from adhering to the lymphatic tissue resulting in reduced infection rates. The present disclosure also relates to oral compositions that can be used to reduce or eliminate oral pathogens in animals.

Described herein are peptides from secretory phospholipase A.sub.2-IB and antibodies that can be used to reduce the contribution of the gastrointestinal tract to inflammatory processes including systemic inflammatory responses. Specifically, antibodies that bind specifically a peptide from secretory phospholipase A.sub.2-IB prevent death in a mouse model of LPS-induced endotoxemia. The antibodies described herein are particularly useful to treat systemic inflammatory response syndromes, including sepsis.

The present invention provides compositions, kits, and methods for the detection of host cell proteins (HCPs) in biological samples. In some embodiments, the present invention utilizes immunization of aves hosts with proteins derived from non-aves host cells to produce aves antibodies specific for non-aves HCPs.

The present disclosure is directed to interleukin-10 (IL-10) peptides and isolated antibodies that specifically bind to the IL-10 peptides. The IL-10 peptides and the isolated antibodies may be administered alone or as an animal feed additive to treat gastrointestinal protozoan infection in animals.

The invention relates to the discovery and characterization of mannan binding lectin-associated serine protease-2 (MASP-2), a new serine protease that acts in the MBLectin complement fixation pathway.

Human pancreatic cancer cells possess a distinct plasma membrane CCK receptor variant that can be differentiated from the classic CCK-B receptor with selective monoclonal antibodies. Use of this receptor may be helpful in early detection or treatment of patients with pancreatic cancer.

The present invention relates to immunoglobulin yolk (IgY) against coxsackievirus A16 and/or enterovirus A71 and its preparation and uses thereof.

A composition and method for therapeutic or prophylactic treatment of mammals includes a mixture of IgY antibodies derived from one or more eggs laid by one or more avian species, wherein each of the one or more avian species have been vaccinated with one or more of the plurality of antigens. The mixture of IgY antibodies can be combined with a protective material that includes colostrum. In some embodiments the composition can also include IgA and IgM antibodies.

In one aspect, the present disclosure is directed to a method for preventing or treating alcoholic liver disease or graft-versus-host disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmunized egg product obtained from an egg-producing animal, thereby preventing or treating the alcoholic liver disease or the graft-versus-host disease in the subject, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to an antigen selected from the group consisting of Enterococcus faecalis, Enterococcus faecalis cytolysin toxin, and Enterococcus faecium. The present disclosure is also directed to hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen selected from the group consisting of Enterococcus faecalis, isolated Enterococcus faecalis cytolysin toxin, and Enterococcus faecium. Methods of preparing the hyperimmunized eggs and egg products are also disclosed.

In one aspect, the present disclosure is directed to a method for preventing or treating alcoholic liver disease or graft-versus-host disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmunized egg product obtained from an egg-producing animal, thereby preventing or treating the alcoholic liver disease or the graft-versus-host disease in the subject, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to an antigen selected from the group consisting of Enterococcus faecalis, Enterococcus faecalis cytolysin toxin, and Enterococcus faecium. The present disclosure is also directed to hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen selected from the group consisting of Enterococcus faecalis, isolated Enterococcus faecalis cytolysin toxin, and Enterococcus faecium. Methods of preparing the hyperimmunized eggs and egg products are also disclosed.